Village Farms: Analyst Consensus Points To Positive Q2 EBITDA Of $1.31 Million

Village Farms International, Inc. (TSX: VFF)  announced that they will be reporting their second quarter financials before market open on August 9.

Analysts have a consensus C$23.39 12-month price target on the company, via a total of 6 analysts, with one analyst having a strong buy rating, and the other five have buy ratings. The street high comes from Raymond James with a C$32.84 price target, and the lowest target comes from Craig Hallum with a C$16 price target.

5 analysts have revenue estimates for the second quarter. The mean between all 5 is C$62.99 million; this number has been revised slightly downwards from C$66.40 million at the start of the year. The street high is C$66.70 million while the lowest sits at C$58.91 million.

Three analysts have estimates for what this quarter’s gross profit margin will be. They expect the profit margin to come in at 10.2%, with this number being revised downwards from 20.85% at the start of the year. Street high goes to Craig Hallum with a 12.30% estimate and the lowest sits at 6.30%.

Onto EBITDA estimates, there are currently only 5 analysts who have second quarter EBITDA estimates. The mean is currently C$1.31 million, with this number being lower at the start of the year. Street high goes to Craig Hallum with a C$2.25 million EBITDA estimate and the lowest being a C$0.5 million estimate.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

This Gold Explorer Is Making Its Biggest Bet | Brian Miller – Astra Exploration

This Gold Discovery Just Keeps Getting Bigger | Roger Rosmus – Goliath Resources

8 Mining Stocks Our Viewers Asked Us to Review | Sept 14th-18th

Recommended

This Gold Discovery Just Keeps Getting Bigger | Roger Rosmus – Goliath Resources

Cardiol Expands MAVERIC Trial to Up to 150 Patients After Reaching Enrollment Target Early

Related News

Aphria: Consensus Estimates For Q3 2021

Aphria Inc (TSX: APHA) (NASDAQ: APHA) is expected to report their fiscal third quarter on...

Wednesday, April 7, 2021, 02:41:00 PM

Uranium Energy Corp: Haywood Reiterates $6.60 Target, Top Pick Rating

On June 8th, Uranium Energy Corp (NYSE: UEC) announced that it had closed a number...

Sunday, June 12, 2022, 04:16:00 PM

Tilray Sees Jefferies Lower Target Due To Canadian Cannabis Headwinds

Jefferies lowered their price target on Tilray Brands (TSX: TLRY), after updating their outlook, saying...

Sunday, April 10, 2022, 01:03:00 PM

BMO: IAMGOLD’s Review Of Cote Operations Expected To Be Negative

On April 18, BMO Capital Markets lowered their 12-month price target and downgraded IAMGOLD Corporation...

Tuesday, April 19, 2022, 05:16:00 PM

K92 Mining Sees Analysts Reiterate Ratings Following Drill Results

Last week, K92 Mining Inc. (TSX: KNT) reported their Judd Vein System drill results, which...

Sunday, September 5, 2021, 04:50:00 PM